Highly anticipated trial results expected soon could move all three of these biotechs

[cafead]

via Sangamo Therapeutics, Inc. (NASDAQ:SGMO), Esperion Therapeutics, Inc.(NASDAQ:ESPR), and Loxo Oncology, Inc. (NASDAQ:LOXO) are all scheduled to present highly anticipated trial results in September that could boost expectations for their experimental therapies. Here's what could go right or wrong in the weeks ahead.

article source